CNBX Pharmaceuticals Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CNBX research report →
Price Chart
About the company
CNBX Pharmaceuticals Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing cannabinoid-based treatments and therapies for various cancers. Its flagship product candidate, RCC-33, is an oral capsule formulation of cannabinoids specifically engineered for treating colorectal cancer.
- CEO
- Eyal Barad
- IPO
- 2007
- Employees
- 1
- HQ
- Bethesda, MD, US
Get TickerSpark's AI analysis on CNBX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $18.50K
- P/E
- -1.00
- PEG
- -0.00
- P/S
- 0.00
- P/B
- -0.10
- EV/EBITDA
- -0.30
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 18.01%
- ROIC
- 16.91%
Latest fiscal year · YoY change
- Revenue
- $0-100.0%
- Gross Profit
- $0-100.0%
- Op Income
- $-271,691
- Net Income
- $-313,976+54.8%
- EPS
- $-0.00+84.8%
- OCF Growth
- +29.9%
- FCF Growth
- +30.2%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 0.81
- RSI (14)
- 60
- Avg Volume
- 8.95M
No earnings-call transcripts are available for CNBX yet.
- Free Float
- 99.9%
- Shares Outstanding
- 92.51M
- Float Shares
- 92.42M
of shares held by institutions
1 13F filers
Buy/sell ratio 3.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 25, 14 | Cannabics Inc. | sell | 18,239,594 |
| Jun 23, 14 | Cannabics Inc. | sell | 14,525,000 |
| May 8, 14 | Cannabics Inc. | sell | 20,500,000 |
| May 8, 14 | MILLS THOMAS E | sell | 20,500,000 |
| Apr 25, 14 | MILLS THOMAS E | sell | 20,500,000 |
| Oct 28, 13 | MILLS THOMAS E | buy | 20,000,000 |
| Oct 28, 13 | MILLS THOMAS E | buy | 20,000,000 |
| Jun 28, 13 | MILLS THOMAS E | other | 20,000,000 |
| Jun 24, 13 | MILLS THOMAS E | buy | 20,000,000 |
| Nov 8, 11 | North American Mining Corp | other | 31,000,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CNBX coverage
Recent articles, reports, and earnings notes.
No research on CNBX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CNBX report →CNBX Pharmaceuticals Inc. (OTCMKTS:CNBX) Short Interest Update
defenseworld.net · Feb 1
Short Interest in CNBX Pharmaceuticals Inc. (OTCMKTS:CNBX) Drops By 97.5%
defenseworld.net · Jan 14
CEO of Cannabics Pharmaceuticals, Eyal Barad, to present at Edison Open Forum: Cannabinoids 2021
prnewswire.com · Oct 19
Cannabics Pharmaceuticals Announces Two New Provisional Patents: Compositions and Methods For Treating Cancer
benzinga.com · Oct 18
Cannabics Pharmaceuticals Files 2 Provisional Patents On Compositions and Methods for Treating Cancer
prnewswire.com · Oct 18
Cannabics Announces New Corporate Logo, New Website and New Company Presentation
prnewswire.com · Sep 30
Gabriel Yariv, Executive Director of Cannabics Pharmaceuticals and Dr. David Sans will participate at the ICDP Summit in Boston
prnewswire.com · Sep 22
Cannabics Pharmaceuticals hires Healthcare Investment Banker Dr. David Sans in New York to expand CNBX in Mental Health Diseases
prnewswire.com · Sep 21
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.